RT @nathanpsmad: 🔥Interesting #RCT for #COVID19 #SARS_CoV_2 Interferon beta-1b, lopinavir–ritonavir, ribavirin in MILD patients (0 death,…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @smoertelt: This was published the other day in the @TheLancet - interferon beta-1b, lopinavir–ritonavir, and ribavirin for COVID-19 pat…
RT @Fraslin: Cette association n'est pas un des bras de Discovery...
RT @srrezaie: Triple therapy with interferon beta-1b, lopinavir-ritonavir, & ribavirin used early in illness shortened virus shedding, alle…
RT @Fraslin: Triple combinaison d'interféron bêta-1b, de lopinavir – ritonavir et de ribavirine dans le traitement des patients admis à l'h…
Cette association n'est pas un des bras de Discovery...
Un tratamiento de dos semanas de terapia antiviral con interferón beta-1b más lopinavir-ritonavir y ribavirina, podría se eficaz, en pacientes con enfermedad, de leve a moderada https://t.co/BO0QZ31n8g @Coronavirus_NF @doctorgaona @oriolmitja https://t
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @Fraslin: Triple combinaison d'interféron bêta-1b, de lopinavir – ritonavir et de ribavirine dans le traitement des patients admis à l'h…
Triple combinaison d'interféron bêta-1b, de lopinavir – ritonavir et de ribavirine dans le traitement des patients admis à l'hôpital avec COVID-19: un essai ouvert, randomisé, de phase 2. https://t.co/xKY4qy2zOI
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @nataliexdean: Earlier treatments. Antivirals are likely more effective when given early in the course of illness. So far we have been…
RT @carpe_diem0820: 非重症COVID-19患者への早期カレトラ+リバビリン+IFβ1b vs カレトラ治療の研究 併用群でPCT陰性化が早く入院期間が短い Triple combination of interferon beta-1b, lopinavi…
RT @nataliexdean: Earlier treatments. Antivirals are likely more effective when given early in the course of illness. So far we have been…
Looks like we finally have a trial with a good looking treatment, but no deaths in 127 consecutive patients? https://t.co/YZpuVfQP6H
Earlier treatments. Antivirals are likely more effective when given early in the course of illness. So far we have been focusing on severely ill patients, but expect more trials in patients earlier in the course of illness. 3/8 https://t.co/rRVQVG9Awl
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial - The Lancet https://t.co/WB6131bYT7
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @EricTopol: Very encouraging randomized trial results for interferon β-1b in mild to moderate #COVID19: marked reduction viral shedding,…
RT @EricTopol: Links and details for the 2 published trials https://t.co/OBWzhQrLPt https://t.co/AydJFDFGFF
RT @TerhiTapiainen: Lupaava tulos ja kaikki käytetyt lääkkeet myös Suomessa saatavilla; IFN toki ongelmallinen sillä vaikutus alussa saatta…
1/ “Triple combination of interferon beta-1b, lopinavir-ritonavir and ribavirin in the treatment of patients with COVID-19: open label, randomized trial” Creo que estamos ante el peor ensayo clínico en covid publicado hasta la fecha. (hilo) https://t.co
RT @KrishRoyLab: This is significant. A combination of drugs, approved for other indications, could be key to faster/better recovery from #…
ICYMI, new study out from @TheLancet on a combination drug treatment for #COVID19 cut time to recover in half, but patients were much less sick.
RT @smoertelt: This was published the other day in the @TheLancet - interferon beta-1b, lopinavir–ritonavir, and ribavirin for COVID-19 pat…
RT @smoertelt: This was published the other day in the @TheLancet - interferon beta-1b, lopinavir–ritonavir, and ribavirin for COVID-19 pat…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/PyQwcFJEdy
This was published the other day in the @TheLancet - interferon beta-1b, lopinavir–ritonavir, and ribavirin for COVID-19 patients...seems to shorten time to negative swab. When looking at the figures I had a bit of a deja-vú... https://t.co/2qFFiziAXF
RT @InternosPy: 🚨🆕 Triple combinación de interferón beta-1b, lopinavir-ritonavir y ribavirina en el tratamiento de pacientes ingresados e…
RT @AndyBiotech: #COVID19 Hopeful data of the day Triple combo of interferon beta-1b + ribavirin + Kaletra shown to be superior to Kaletra…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial - The Lancet https://t.co/VUtXYFmLjw
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
🚨🆕 Triple combinación de interferón beta-1b, lopinavir-ritonavir y ribavirina en el tratamiento de pacientes ingresados en el hospital con COVID-19: un ensayo fase ll, abierto, aleatorizado. Artículo completo(inglés)⏬ https://t.co/X6N3zWVxAN Resumen en
RT @biblioGetafe: Multicentre randomised open-label phase 2 trial in patients #COVID19, triple combination therapy of injectable interferón…
Multicentre randomised open-label phase 2 trial in patients #COVID19, triple combination therapy of injectable interferón beta-1b, oral protease inhibitor (lopinavir–ritonavir) and oral nucleoside analogue (ribavirin) The Lancet https://t.co/ak4o3zzd3L htt
RT @nathanpsmad: 🔥Interesting #RCT for #COVID19 #SARS_CoV_2 Interferon beta-1b, lopinavir–ritonavir, ribavirin in MILD patients (0 death,…
Encouraging early results from study assessing efficacy of combined interferon beta-1b, lopinavir–ritonavir & ribavirin on #COVID19 patients. Seems to alleviate symptoms, shorten duration of viral shedding & hospital stay for moderate cases. @TheLa
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial - The Lancet https://t.co/szpuOzBXGb @chrismartenson
Triple Combination of Interferon Beta-1b, Lopinavir–Ritonavir, and Ribavirin Alleviates Symptoms in Mild to Moderate COVID-19 Patients | @scoopit https://t.co/UFyxJxt221
RT @davenjoe76: I was thinking that I wish there will be more studies/trials of early treatment (patient with mild symptoms) after reading…
RT @EricTopol: Very encouraging randomized trial results for interferon β-1b in mild to moderate #COVID19: marked reduction viral shedding,…
RT @tipssovetorax: Terapia antiviral triple en fase temprana fue segura y superior al lopinavir-ritonavir solo, en alivio de síntomas y aco…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/N4xn1ZsWjl
Terapia antiviral triple en fase temprana fue segura y superior al lopinavir-ritonavir solo, en alivio de síntomas y acortar la duración de viremia, estancia hospitalaria en pacientes COVID-19 leve/moderado/2 https://t.co/byiSpvBiXq
#COVID19 Triple combinación: Interferon beta-1b, lopinavir/ritonavir, rivabirina. Ensayo clínico fase 2. @SOVETORAX https://t.co/byiSpvBiXq
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
Good research out of Hong Kong. “Most patients treated with the triple combination were RT-PCR negative in all specimens by day 8.” This is much shorter than what we have seen in those without treatment (avg 25d). A phase 2 trial - The Lancet https://t.co/
Latest research on covid-19 medicine!! kindly click here to know..... https://t.co/M5alxdALml #Bangladesh #BangladeshisLoveSid #COVID19 #covid19usa
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial - The Lancet https://t.co/t1GcHoAweK
RT @Derek_Leong_RPh: Small, open-label RCT in hospitalized #COVID19 Pts showing Kaletra + ribavirin x14d +/- interferon (0-3 doses) ⬇️time…
RT @AndyBiotech: #COVID19 Hopeful data of the day Triple combo of interferon beta-1b + ribavirin + Kaletra shown to be superior to Kaletra…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @rplenge: In an open-label, randomized Ph2 trial of n=127 COVID-19 patients, IFN-beta-1b (as part of triple therapy) was found to allevi…
RT @influenzer3: ●昨日、新聞記事で紹介した3剤併用療法について →RBV+ IFN-β-1b+LPV/rの3剤併用とLPV/r単剤とのRCT。 併用群がウイルス量を有意に減らし、臨床症状を改善させ、IL-6を低下させたという結果です。 副作用がLPV/r単剤と…
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @EmilioAlegre1: ECA fase2 triple terapia (L/r+RBV+IFN-B sc) vs. L/r en 162 vs 81 pacientes PCR+ hospitalizados. Pero en Hong Kong, donde…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19. https://t.co/p1CSCrjZfZ
RT @EmilioAlegre1: ECA fase2 triple terapia (L/r+RBV+IFN-B sc) vs. L/r en 162 vs 81 pacientes PCR+ hospitalizados. Pero en Hong Kong, donde…
Whilst in SA Kaletra is not a first line treatment, we still need to ensure we take care of our ART supply for 1st, 2nd line treatments. We saw what happened with Hydroxychloroquine supply. We must make sure our people living with HIV do not get sidelined.
RT @segawashin: COVID19患者に対する治験。lopinavirとritonavir単独の場合と、これに加えてribavirinとインターフェロン投与群を二重盲検、後者のほうが複数箇所のサンプルでウイルス減少が有意に顕著だった……ということみたい。香港のグルー…
RT @srrezaie: Triple therapy with interferon beta-1b, lopinavir-ritonavir, & ribavirin used early in illness shortened virus shedding, alle…
5. This trial supports the idea that ritonavir can potentiate the activity of chain terminating drugs such as ribavirin, remdesivir and favipiravir. https://t.co/3xnkIkxrGF
4. A combination of lopinavir-ritonavir, ribavirin and interferon beta-1b significantly reduced hospitalization time in COVID-19 patients. https://t.co/3xnkIkxrGF
RT @EmilioAlegre1: ECA fase2 triple terapia (L/r+RBV+IFN-B sc) vs. L/r en 162 vs 81 pacientes PCR+ hospitalizados. Pero en Hong Kong, donde…
RT @dtnair: https://t.co/3xnkIkxrGF this clinical trial supports the idea that ritonavir will enhance the effect of chain terminators (riba…
RT @gorka_orive: Un ensayo clínico demuestra que la combinación de interferon beta-1b, lopinavir–ritonavir, y ribavirina en el tratamiento…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/gX5T6p1yH2
ECA fase2 triple terapia (L/r+RBV+IFN-B sc) vs. L/r en 162 vs 81 pacientes PCR+ hospitalizados. Pero en Hong Kong, donde TODOS los PCR+ van al hospital, así que son jóvenes (52 años), 60% sin comorbilidades, 40% diabetes/HTA. Esa es la clave del estudio. h
RT @carpe_diem0820: 非重症COVID-19患者への早期カレトラ+リバビリン+IFβ1b vs カレトラ治療の研究 併用群でPCT陰性化が早く入院期間が短い Triple combination of interferon beta-1b, lopinavi…
RT @srrezaie: Triple therapy with interferon beta-1b, lopinavir-ritonavir, & ribavirin used early in illness shortened virus shedding, alle…
RT @ABsteward: Mild category based on NEWS score and SOFA Do you find it logical to treat mild /mod #COVID19 with this combination of 3 dru…
RT @carpe_diem0820: 非重症COVID-19患者への早期カレトラ+リバビリン+IFβ1b vs カレトラ治療の研究 併用群でPCT陰性化が早く入院期間が短い Triple combination of interferon beta-1b, lopinavi…
RT @IImmunology_TCD: Hopeful Therapeutic Approach for COVID-19 @TheLancet. Interesting: The inflammatory cytokine IL-6, was significantly…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/Ob83eHF3gE
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
@amitabhk87 1. https://t.co/Myr3c784Cx 2. https://t.co/ZPu8eD9uqE 3. https://t.co/8we76NFmtT Kindly have a look at these too. @amitabhk87 @ArvinderSoin
非重症COVID-19患者への早期カレトラ+リバビリン+IFβ1b vs カレトラ治療の研究 併用群でPCT陰性化が早く入院期間が短い Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 https://t.co/9rNG5Ehmn5 https://t.co/AjYSAJlSt
Early studies on IFN-B and some positive results shown. SNG001 is much safer and dosages controlled hence why we have auth for home trials. great entry to also top up :) #SNG https://t.co/Ev04WMVHjI
RT @richardhorton1: Important early new data on combination treatment for mild-moderate COVID-19. Extremely encouraging. https://t.co/hG2ae…
RT @richardhorton1: Important early new data on combination treatment for mild-moderate COVID-19. Extremely encouraging.
RT @srrezaie: Triple therapy with interferon beta-1b, lopinavir-ritonavir, & ribavirin used early in illness shortened virus shedding, alle…
RT @influenzer3: ●昨日、新聞記事で紹介した3剤併用療法について →RBV+ IFN-β-1b+LPV/rの3剤併用とLPV/r単剤とのRCT。 併用群がウイルス量を有意に減らし、臨床症状を改善させ、IL-6を低下させたという結果です。 副作用がLPV/r単剤と…
@SaludSV @nayibbukele @_ElFaro_ @UCA_ES Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/XgkKaqMMam
RT @INERsticio: We must change our strategy to treat COVID19 We propose the sooner the better. https://t.co/8zLk9mge2j
RT @EricTopol: Very encouraging randomized trial results for interferon β-1b in mild to moderate #COVID19: marked reduction viral shedding,…
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://t.co/7TYIulDccK
RT @richardhorton1: Important early new data on combination treatment for mild-moderate COVID-19. Extremely encouraging. https://t.co/hG2ae…
New and intriguing!
RT @srrezaie: Triple therapy with interferon beta-1b, lopinavir-ritonavir, & ribavirin used early in illness shortened virus shedding, alle…
Ein Medikamenten-Cocktail aus #Interferon_beta1b, #Lopinavir_Ritonavir und #Ribavirin soll laut einer im The Lancet veröffentlichten Studie erste Erfolge bei Patienten mit einem milden bis moderaten #Covid_19 Verlauf zeigen. https://t.co/3szsCPAPfb
RT @TheLancet: NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise…
RT @lucavalenti75: back to ifn+rbv?